Verastem(VSTM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VSTM Verastem

盘前交易 06-29 07:52:37 EDT

3.78

+0.33

+9.57%

盘前3.67

-0.11-2.86%

07:37 EDT

最高3.82	最低3.44	成交量802.78万
今开3.50	昨收3.45	日振幅11.16%
总市值3.32亿	流通市值2.84亿	总股本8,784万
成交额2,980万	换手率10.70%	流通股本7,506万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VSTM","market":"US","secType":"STK","nameCN":"Verastem","latestPrice":3.78,"timestamp":1782504000000,"preClose":3.45,"halted":0,"volume":8027834,"hourTrading":{"tag":"盘前","latestPrice":3.672,"preClose":3.78,"latestTime":"07:37 EDT","volume":1904,"amount":7023.1985488,"timestamp":1782733061311,"change":-0.108,"changeRate":-0.028571,"amplitude":0.04709},"delay":0,"changeRate":0.09565217391304337,"floatShares":75061500,"shares":87835106,"eps":-2.414264,"marketStatus":"盘前交易","change":0.33,"latestTime":"06-29 07:52:37 EDT","open":3.5,"high":3.82,"low":3.435,"amount":29803106.5372978,"amplitude":0.111594,"askPrice":3.76,"askSize":379,"bidPrice":3.34,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.414264,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782739800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1327640400000,"exchange":"NASDAQ","adjPreClose":3.78,"preHourTrading":{"tag":"盘前","latestPrice":3.672,"preClose":3.78,"latestTime":"07:37 EDT","volume":1904,"amount":7023.1985488,"timestamp":1782733061311,"change":-0.108,"changeRate":-0.028571,"amplitude":0.04709},"postHourTrading":{"tag":"盘后","latestPrice":3.7501,"preClose":3.78,"latestTime":"19:46 EDT","volume":547389,"amount":2068581.1,"timestamp":1782517612602,"change":-0.0299,"changeRate":-0.00791,"amplitude":0.050265},"volumeRatio":2.3770988146209615,"impliedVol":8.1353,"impliedVolPercentile":0.996},"requestUrl":"/m/hq/s/VSTM","defaultTab":"news","newsList":[{"id":"1171317225","title":"VS-7375在晚期KRAS G12D突变实体瘤患者的Target-D 101 I/II期临床试验中展现临床活性，安全性与耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1171317225","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171317225?lang=zh_cn&edition=full","pubTime":"2026-06-24 04:02","pubTimestamp":1782244952,"startTime":"0","endTime":"0","summary":"在针对晚期KRAS G12D突变实体瘤患者开展的Target-D 101 I/II期临床试验中，候选药物VS-7375显示出积极的临床活性信号，同时其安全性与耐受性特征表现良好。该试验结果初步验证了该药物在这一难治性患者群体中的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187616620","title":"Verastem公布RAMP 205研究积极更新数据：Avutometinib联合Defactinib及标准化疗一线治疗转移性胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1187616620","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187616620?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:31","pubTimestamp":1781695879,"startTime":"0","endTime":"0","summary":"Verastem Oncology近日公布了RAMP 205研究的积极更新结果。该研究旨在评估Avutometinib联合Defactinib，并与标准护理化疗方案相结合，用于一线治疗转移性胰腺癌患者的疗效与安全性。\n最新数据显示，这一联合疗法展现出令人鼓舞的临床活性。研究结果进一步支持了该组合疗法在应对这一难治性癌症方面的潜在价值。胰腺癌治疗领域长期面临挑战，此次更新为患者带来了新的希望。\n公司将继续推进相关临床开发计划，深入探索该联合疗法在更大患者群体中的表现。这些积极进展也为后续的临床策略与潜在监管申请奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130135230","title":"Verastem Oncology启动VS-7375治疗Kras G12d突变胰腺癌II期注册试验，首位患者已用药","url":"https://stock-news.laohu8.com/highlight/detail?id=1130135230","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130135230?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:02","pubTimestamp":1781640137,"startTime":"0","endTime":"0","summary":"Verastem Oncology宣布，其针对Kras G12d突变转移性胰腺癌的口服抑制剂VS-7375，已在名为Target-D 201的II期注册导向试验中，为第一位患者完成给药。这项关键性研究旨在评估该药物的疗效与安全性，标志着该创新疗法向潜在注册上市迈出了实质性一步。VS-7375是一种新型的Kras G12d（开/关）抑制剂，其设计旨在精准靶向这一在胰腺癌中常见的特定基因突变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131158197","title":"Verastem Oncology宣布口服潜在同类最佳在研药物VS-7375获美国FDA快速通道认定，用于治疗KRAS G12D突变局部晚期或转移性非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1131158197","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131158197?lang=zh_cn&edition=full","pubTime":"2026-06-04 04:02","pubTimestamp":1780516936,"startTime":"0","endTime":"0","summary":"Verastem Oncology宣布，其口服、潜在同类最佳在研KRAS G12D（开/关）抑制剂VS-7375，已获得美国食品药品监督管理局（FDA）的快速通道认定。该药物旨在用于治疗携带KRAS G12D突变的局部晚期或转移性非小细胞肺癌（NSCLC）患者。\n快速通道认定旨在加速针对严重疾病且能填补未满足医疗需求的药物的开发和审评进程。这一认定意味着VS-7375有潜力解决KRAS G12D突变NSCLC这一关键临床需求领域。对于Verastem而言，这是其管线推进的一个重要监管里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638545418","title":"Verastem Oncology任命Michael P. Bailey为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2638545418","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638545418?lang=zh_cn&edition=full","pubTime":"2026-05-26 23:17","pubTimestamp":1779808620,"startTime":"0","endTime":"0","summary":"专注于RAS/MAPK通路驱动型癌症的生物制药公司Verastem Oncology今日宣布，任命Michael P． Bailey为公司董事会成员。与此同时，Robert Gagnon于2026年5月21日任期届满后正式卸任。　　Bailey现任LG化学旗下AVEO Pharmaceuticals总裁兼首席执行官，并自2015年1月起担任该公司董事。　　Verastem Oncology近期财务表现稳健。随着公司推进LGSOC业务并在2026年下半年实现自给自足的目标，Bailey在肿瘤药物商业化和产品全生命周期管理方面的深厚经验有望为董事会带来战略价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-26/doc-inhzfwqk1335245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636894151","title":"高德红绿灯倒计时宣布出海，将逐步覆盖全球","url":"https://stock-news.laohu8.com/highlight/detail?id=2636894151","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636894151?lang=zh_cn&edition=full","pubTime":"2026-05-20 10:50","pubTimestamp":1779245400,"startTime":"0","endTime":"0","summary":"新浪科技讯 5月20日上午消息，高德红绿灯倒计时宣布出海，将在全球更多国家和地区逐步落地。　　红绿灯倒计时是阿里巴巴旗下高德于2022年5月推出的产品功能，基于AI技术，能够对路口信号灯变化进行实时模拟与计算。　　截至目前，高德红绿灯倒计时已在中国大陆及港澳台地区全面落地，覆盖红绿灯路口近50万个，有效提升了交通路口的通行效率与安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2026-05-20/doc-inhyphnp1715201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136532289","title":"Verastem Oncology公布Avmapki®与Fakzynja®联合疗法（Avutometinib胶囊；Defactinib片剂）治疗复发性低级别浆液性卵巢癌的两年中位随访数据，亮相2026年SGO女性癌症年会","url":"https://stock-news.laohu8.com/highlight/detail?id=1136532289","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136532289?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:01","pubTimestamp":1775818900,"startTime":"0","endTime":"0","summary":"Verastem Oncology在2026年妇科肿瘤学会（SGO）女性癌症年度会议上，公布了其Avmapki®与Fakzynja®联合疗法（即Avutometinib胶囊与Defactinib片剂）用于治疗复发性低级别浆液性卵巢癌的两年中位随访数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611112240","title":"Verastem, Inc.盘中异动 早盘快速拉升5.39%报6.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2611112240","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611112240?lang=zh_cn&edition=full","pubTime":"2026-02-13 23:45","pubTimestamp":1770997553,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日23时45分，Verastem, Inc.股票出现异动，股价急速上涨5.39%。截至发稿，该股报6.16美元/股，成交量40.006万股，换手率0.53%，振幅3.89%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为2.01%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213234554a6f84ca4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213234554a6f84ca4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608989853","title":"Verastem, Inc.盘中异动 早盘急速上涨5.24%报6.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608989853","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608989853?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:36","pubTimestamp":1770215778,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日22时36分，Verastem, Inc.股票出现波动，股价大幅上涨5.24%。截至发稿，该股报6.63美元/股，成交量25.455万股，换手率0.34%，振幅3.49%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.80%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204223618a47c5451&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204223618a47c5451&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176027781","title":"Verastem计划于2026年上半年与FDA会晤，共商胰腺癌、非小细胞肺癌及结直肠癌新药开发路径与注册导向临床试验方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1176027781","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176027781?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:38","pubTimestamp":1770208708,"startTime":"0","endTime":"0","summary":"生物制药公司Verastem近日披露，将于2026年上半年与美国食品药品监督管理局（FDA）展开正式对话，旨在明确其创新疗法的后续开发策略。此次会议将重点探讨针对胰腺癌（PDAC）、非小细胞肺癌（NSCLC）及结直肠癌（CRC）等实体瘤的潜在注册导向型临床试验设计框架。这一关键步骤标志着公司核心研发项目向商业化迈进的重要节点，也为未来加速创新疗法上市奠定监管基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158305584","title":"Verastem预计LGSC商业化上市及开发项目将于2026年下半年实现自给自足","url":"https://stock-news.laohu8.com/highlight/detail?id=1158305584","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158305584?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:33","pubTimestamp":1770208405,"startTime":"0","endTime":"0","summary":"生物制药公司Verastem近日宣布，其针对低级别浆液性卵巢癌的创新疗法商业化进程取得重大进展。公司预计，该项目的全面上市与后续研发计划最晚将于2026年下半年实现资金自循环，不再依赖外部资本注入。这一里程碑式的进展源于Verastem在临床开发与市场布局方面的双重突破。分析师指出，若该时间表如期实现，Verastem将成为罕见妇科肿瘤领域首个通过单一产品线实现财务独立的生物技术企业。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158797144","title":"Verastem预计2025年第四季度Avmapki Fakzynja联合包装产品净收入约1750万美元，2025年全年约3090万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1158797144","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158797144?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:33","pubTimestamp":1770208389,"startTime":"0","endTime":"0","summary":"Verastem公司发布预测，其Avmapki Fakzynja联合包装产品在2025年第四季度的净收入预计将达到约1750万美元。同时，该公司对2025年全年的业绩也给出了乐观展望，预计该产品的全年净收入总额约为3090万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145676997","title":"Verastem Oncology 公布2025年第四季度及全年初步营收与业务进展，并规划2026年针对Ras/Mapk通路驱动癌症创新产品组合的战略重点","url":"https://stock-news.laohu8.com/highlight/detail?id=1145676997","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145676997?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:30","pubTimestamp":1770208216,"startTime":"0","endTime":"0","summary":"Verastem Oncology 近日披露了其2025年第四季度及全年的初步营收数据与业务最新动态，同时明确了2026年的核心战略方向，将重点聚焦于针对Ras/Mapk信号通路驱动型癌症的创新药物组合。\n公司概述了未来一年的关键优先事项，旨在加速其新型疗法组合的开发与商业化进程，这些疗法专门设计用于对抗由Ras/Mapk通路异常激活所引发的各类癌症。此次更新突显了公司致力于在该关键肿瘤学领域取得突破性进展的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122401255","title":"Verastem Oncology公布RAMP 203治疗晚期KRAS G12C突变非小细胞肺癌的1/2期临床试验进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1122401255","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122401255?lang=zh_cn&edition=full","pubTime":"2025-12-30 05:02","pubTimestamp":1767042143,"startTime":"0","endTime":"0","summary":"Verastem Oncology近日针对其RAMP 203 1/2期临床试验发布了最新动态。该试验主要聚焦于晚期携带KRAS G12C突变的非小细胞肺癌患者的治疗方案评估。此次更新涉及临床试验的具体推进情况与相关数据，为后续研发路径提供重要参考。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518220886","title":"Verastem, Inc.盘中异动 大幅上涨5.14%报7.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518220886","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518220886?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:49","pubTimestamp":1741625371,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日00时49分，Verastem, Inc.股票出现异动，股价快速拉升5.14%。截至发稿，该股报7.36美元/股，成交量51.1809万股，换手率1.15%，振幅7.43%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004931abf344c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311004931abf344c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513211811","title":"Verastem, Inc.盘中异动 股价大涨5.21%报5.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513211811","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513211811?lang=zh_cn&edition=full","pubTime":"2025-02-22 03:23","pubTimestamp":1740165786,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时23分，Verastem, Inc.股票出现异动，股价急速拉升5.21%。截至发稿，该股报5.86美元/股，成交量28.4278万股，换手率0.64%，振幅4.94%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222032306abd7ea85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222032306abd7ea85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512231196","title":"Verastem, Inc.盘中异动 大幅下挫5.03%报5.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512231196","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512231196?lang=zh_cn&edition=full","pubTime":"2025-02-19 03:09","pubTimestamp":1739905785,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日03时09分，Verastem, Inc.股票出现波动，股价急速下挫5.03%。截至发稿，该股报5.67美元/股，成交量30.2897万股，换手率0.68%，振幅5.53%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.90%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219030945a24ae609&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219030945a24ae609&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510891292","title":"Verastem, Inc.盘中异动 下午盘大幅下挫5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510891292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510891292?lang=zh_cn&edition=full","pubTime":"2025-02-11 03:28","pubTimestamp":1739215689,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日03时28分，Verastem, Inc.股票出现波动，股价大幅下挫5.01%。Verastem, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。其相关个股中，Dominari Holdings Inc.、Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.涨幅较大，Biodexa Pharmaceuticals Plc、Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.较为活跃，换手率分别为3139.85%、1672.88%、1411.40%，振幅较大的相关个股有Immatics N V C/Wts 01/07/2025 、Biodexa Pharmaceuticals Plc、Abpro Holdings Inc C/Wts 12/11/2029 ，振幅分别为99.86%、92.63%、87.80%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211032809a240deb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211032809a240deb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508993691","title":"B. Riley Securities：维持Verastem(VSTM.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508993691","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508993691?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:39","pubTimestamp":1738345141,"startTime":"0","endTime":"0","summary":"B. Riley Securities：维持Verastem(VSTM.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至9.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/01013947922571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506025203","title":"Verastem, Inc.盘中异动 早盘股价大跌5.07%报5.62美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506025203","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506025203?lang=zh_cn&edition=full","pubTime":"2025-01-28 00:25","pubTimestamp":1737995148,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日00时25分，Verastem, Inc.股票出现异动，股价急速跳水5.07%。截至发稿，该股报5.62美元/股，成交量40.5328万股，换手率0.91%，振幅7.26%。Verastem, Inc.股票所在的生物技术行业中，整体涨幅为0.92%。Verastem, Inc.公司简介：Verastem Inc 是一家后期开发生物制药公司，致力于为抗癌患者开发新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280025489874c27b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501280025489874c27b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VSTM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.verastem.com","stockEarnings":[{"period":"1week","weight":-0.0825},{"period":"1month","weight":-0.1106},{"period":"3month","weight":-0.25},{"period":"6month","weight":-0.531},{"period":"1year","weight":-0.0913},{"period":"ytd","weight":-0.5104}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Verastem, Inc.于2010年8月4日注册成立为一家特拉华州公司。该公司是一家处于后期开发阶段的生物制药公司，正在进行注册定向试验，致力于为与癌症作斗争的患者推进新药。该公司的管道专注于抑制癌症中关键信号通路的新型抗癌剂，这些信号通路可促进癌细胞存活和肿瘤生长，特别是RAF/MEK抑制和FAK抑制。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.073347},{"month":2,"riseRate":0.4,"avgChangeRate":-0.007088},{"month":3,"riseRate":0.466667,"avgChangeRate":0.082917},{"month":4,"riseRate":0.466667,"avgChangeRate":-0.020958},{"month":5,"riseRate":0.466667,"avgChangeRate":0.064718},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.05078},{"month":7,"riseRate":0.428571,"avgChangeRate":0.074115},{"month":8,"riseRate":0.357143,"avgChangeRate":0.01437},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.072546},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.101891},{"month":11,"riseRate":0.785714,"avgChangeRate":0.131906},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.064523}],"exchange":"NASDAQ","name":"Verastem","nameEN":"Verastem"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verastem(VSTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Verastem(VSTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Verastem,VSTM,Verastem股票,Verastem股票老虎,Verastem股票老虎国际,Verastem行情,Verastem股票行情,Verastem股价,Verastem股市,Verastem股票价格,Verastem股票交易,Verastem股票购买,Verastem股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verastem(VSTM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Verastem(VSTM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}